Apply to trial NCT06429449

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Drug trial

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening